Headlines about Alcobra (NASDAQ:ADHD) have been trending somewhat positive on Saturday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alcobra earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 87 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern’s analysis:
- Grimes & Company Inc. Cuts Position in Chevron Corporation (NYSE:CVX) (emfizz.com)
- Chevron Corporation (CVX) Stake Raised by Chickasaw Capital Management LLC (leisuretravelaid.com)
- Hochman Cole Investment Advisors Inc. Increases Stake in Chevron Corporation (CVX) (badhub.net)
- Trading Watch on Shares of Alcobra Ltd. Ord (ADHD) – Financial News Review (finnewsreview.com)
- Latin America Attention Deficit Hyperactivity Disorder Therapeutics Market to have bright future during 2016-21 (medgadget.com)
Shares of Alcobra (NASDAQ:ADHD) traded up 0.90% during trading on Friday, hitting $1.12. 111,315 shares of the stock were exchanged. The stock’s market cap is $30.87 million. The stock’s 50 day moving average is $1.14 and its 200-day moving average is $1.18. Alcobra has a 12-month low of $0.83 and a 12-month high of $5.36.
Alcobra (NASDAQ:ADHD) last posted its earnings results on Tuesday, May 30th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Equities research analysts anticipate that Alcobra will post ($0.57) EPS for the current year.
ADHD has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Friday, June 2nd. Roth Capital set a $4.00 price target on shares of Alcobra and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Cantor Fitzgerald reaffirmed a “hold” rating and set a $1.00 price target on shares of Alcobra in a research note on Thursday, April 13th. Jefferies Group LLC reaffirmed a “hold” rating and set a $1.25 price target on shares of Alcobra in a research note on Friday, March 31st. Finally, ValuEngine downgraded shares of Alcobra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $1.93.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.